A Phase 2 interventional study of Ribupatide and Placebo in Obesity, sponsored by Kailera. Active, not recruiting at 35 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-15.
Sponsored by Kailera · Phase 2, Interventional, and Treatment
The primary objective of this study is to determine the effects of ribupatide administered by subcutaneous (SC) injection once weekly compared to placebo on percent change in body weight.
6,296 studies on the registry are indexed under Obesity; 1,692 are open to participants now.
This study's enrollment of 264 is above the median of 78 across 4,878 interventional studies indexed under Obesity.
Browse Obesity studies →Kailera is the lead sponsor of 8 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Additional inclusion/exclusion criteria may apply, per protocol.
Participants will receive Dose 1 of ribupatide once weekly.
Drug: Ribupatide
Participants will receive Dose 2 of ribupatide once weekly.
Drug: Ribupatide
Participants will receive Dose 3 of ribupatide once weekly.
Drug: Ribupatide
Participants will receive Dose 4 of ribupatide once weekly.
Drug: Ribupatide
Participants will receive placebo matched to ribupatide once weekly.
Drug: Placebo
SC Injection
Also known as: KAI-9531
SC Injection
Percent Change From Baseline in Body Weight at Week 48
Time frame: Baseline, Week 48
Percent of Participants with ≥5%, ≥10%, ≥15%, ≥20% and ≥25% Reduction From Baseline in Body Weight
Time frame: Baseline, Week 48
Change From Baseline in Waist Circumference
Time frame: Baseline, Week 48
Change From Baseline in Absolute Body Weight
Time frame: Baseline, Week 48
Change From Baseline in Body Mass Index (BMI)
Time frame: Baseline, Week 48
Percent Change From Baseline in Fasting Triglycerides
Time frame: Baseline, Week 48
Percent Change From Baseline in Fasting High-density Lipoprotein (HDL)-cholesterol
Time frame: Baseline, Week 48
Percent Change From Baseline in Fasting Non-HDL-cholesterol
Time frame: Baseline, Week 48
Percent Change From Baseline in Fasting Total Cholesterol
Time frame: Baseline, Week 48
Percent Change From Baseline in Fasting Low-density Lipoprotein (LDL)-cholesterol
Time frame: Baseline, Week 48
Percent Change From Baseline in Fasting Very Low-density Lipoprotein (VLDL)-cholesterol
Time frame: Baseline, Week 48
Percent Change From Baseline in Fasting Insulin
Time frame: Baseline, Week 48
Change From Baseline in Fasting Blood Glucose
Time frame: Baseline, Week 48
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Time frame: Day 1 up to Week 52
Number of Participants With Anti-drug Antibodies (ADAs)
Time frame: Day 1 up to Week 52
Number of Participants With Neutralizing Antibodies (NAbs)
Time frame: Day 1 up to Week 52
Plasma Concentrations of Ribupatide
Time frame: Day 1 up to Week 52
Plan to share: No
No publications or documents are linked to this record.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Kailera